Ethan Perlstein
CEO @ n-of-1 NewOrg, founder/CEO @PerlaraPBC, cure sherpa, @ycombinator W16, former CSO @ReeveFoundation, cofounder of Kai & Luca
Last synced from Twitter 88d ago
Journey Colab bags $3M from 'moonshot' fund to push new development model for psychedelic treatments
Psychedelics have the potential to become new, better treatments for mental illnesses, but today’s drug development model—not to mention the war on drugs—have hindered their progress. Journey Colab thinks it has the solution, and it’s caught the eye...
Why do bad things happen to good people?
My little bear passed away. He had been battling the fight of his life and decided to slip into heaven a few minutes ago. I am reblogging what I wrote about him some time ago. Hopefully I will be s…
Future Founders Conference 2020
The Future Founders Conference is for women who are thinking about becoming a startup founder. The event will be online, and whether you have a slight interest in startups or are in the early stages of building one, you’ll walk away more...
Treatment for neurological disorder could be repurposed for Huntington’s disease patients
While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation.
Gene Fixers Meetup - The Gene Fixers
Thursday, October 22 at 2:00pm PDT with Ethan Perlstein, Rohan Seth. Join highly motivated parents and researchers on their quests to cure the long tail of genetic diseases
Ethan Perlstein
I'm co-hosting a “Gene Fixers Meetup” with @rohanseth and The Gene Fixers.
Tomorrow, Oct 22 at 2:00 PM PDT on @joinclubhouse.
Join parents and researchers on their quests to cure the long tail of genetic diseases!
95d
Ethan Perlstein
Gene Fixers Meetup with @rohanseth and others in the fight against the long tail of genetic diseases today, Oct 22 at 2:00 PM PDT on @joinclubhouse.
Join us!
94d
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We...
Future Founders Conference for Women Globally
On November 18, we are hosting our first Future Founders Conference for women who aspire to become a startup founder. The event will be online, and whether you are curious about launching your own startup or are in the early stages of building one,...
Exclusive: Osmind Inks $2M To Improve Care Delivery, Treatment For Mental Health
Osmind's software works through electronic health records to deliver care and better outcomes for people who experience treatment-resistant mental health disorders.
Episode 1: Low-N Protein Engineering with Surge Biswas — Fifty Years
First Author : Surojit “Surge” Biswas Paper : Low-N protein engineering with data-efficient deep learning. bioRxiV, 2020. Protein engineering has been dominated by two opposing paradigms; directed evolution, a massive screening technique, and...
Intercellular telomere transfer extends T cell lifespan
The common view is that T-lymphocytes activate telomerase, a DNA polymerase that extends telomeres at chromosome ends, to delay senescence. We show that independently of telomerase, T cells elongate telomeres by acquiring telomere vesicles from...
Hyundai's New Wheelchair Taxi Concept is Out of This World - Wheelchair Travel
Hyundai's New Horizons Studio is focused on developing Ultimate Mobility Vehicles, including a robotic wheelchair taxi concept.
Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria
Uncovering the role of defective metabolism in Parkinson’s disease (PD) may lead to the discovery of disease-modifying therapies. We recently linked branched-chain amino acid (BCAA) metabolism with PD, yet the underlying mechanisms were unknown. We...
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic disease